Publication:
7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate

relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Herrero Ezquerro, María Trinidad ; Yuste Lucas, Juan Luis ; Cuenca Bermejo, Lorena ; Almela Rojo, Pilar ; Arenas-Betancur, L. ; De Pablos, V. ; González Cuello, Ana María ; Del Bel, E. ; Navarro Zaragoza, Javier ; Fernández Villalba, Emiliano
item.page.secondaryauthor
item.page.director
Publisher
The Royal Society Publishing
publication.page.editor
publication.page.department
DOI
https://doi.org/10.1098/rsob.220370
item.page.type
info:eu-repo/semantics/article
Description
©2023. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ This document is the Submitted, Accepted, Published, version of a Published Work that appeared in final form in Open Biology. To access the final edited and published work see https://doi.org/10.1098/rsob.220370
Abstract
Nitric oxide (NO) plays a pivotal role in integrating dopamine transmission in the basal ganglia and has been implicated in the pathogenesis of Parkinson disease (PD). The objective of this study was to ascertain whether the NO synthase inhibitor, 7-nitroindazole (7-NI), is able to reduce L-DOPA induced dyskinesias (LIDs) in a non-human primate model of PD chronically intoxicated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Six Parkinsonian macaques were treated daily with L-DOPA for 3–4 months until they developed LIDs. Three animals were then co-treated with a single dose of 7-NI administered 45 min before each L-DOPA treatment. Dyskinetic MPTP-treated monkeys showed a significant decrease in LIDs compared with their scores without 7-NI treatment ( p < 0.05). The anti-Parkinsonian effect of L-DOPA was similar in all three monkeys with and without 7-NI co-treatment. This improvement was significant with respect to the intensity and duration of LIDs while the beneficial effect of L-DOPA treatment was maintained and could represent a promising therapy to improve the quality of life of PDpatients.
publication.page.subject
Citation
Open Biology 13: 220370
item.page.embargo
Collections